Georgina Buck

• Prospective evaluation of quality of life in children treated in UKALL 2003 for acute lymphoblastic leukaemia: A cohort study.

  Eiser C. et al, (2017), Pediatr Blood Cancer

• Prospective evaluation of quality of life in children treated in UKALL 2003 for Acute Lymphoblastic Leukaemia (ALL): A cohort study

  Eiser C. et al, (2017), Pediatric Blood and Cancer

• Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.

  Kumar AJ. et al, (2016), Am J Hematol, 91, 1107 - 1112

• in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993

  Ganzel C. et al, (2015), BLOOD, 126

• High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): cytogenetic features, clinical characteristics and outcome.

  Chilton L. et al, (2014), Leukemia, 28, 1511 - 1518

• UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

  Fielding AK. et al, (2014), Blood, 123, 843 - 850

• High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): Cytogenetic features, clinical characteristics and outcome

  Chilton L. et al, (2014), Leukemia, 28, 1511 - 1518

• Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort.

  Campbell PJ. et al, (2012), Blood, 120, 1409 - 1411

• Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.

  Sive JI. et al, (2012), Br J Haematol, 157, 463 - 471

• Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial

  Sive JI. et al, (2012), British Journal of Haematology, 157, 463 - 471

• The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI.

  Halsey C. et al, (2011), J Hematol Oncol, 4

• Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups

  Lrrzow MR. et al, (2010), BLOOD, 116, 232 - 233

• Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial

  Sive JI. et al, (2010), BLOOD, 116, 218 - 219

• Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial

  Fielding AK. et al, (2010), BLOOD, 116, 77 - 77

• Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups - a UKALLXII study.

  Rai L. et al, (2010), Br J Haematol, 148, 394 - 401

• Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.

  Patel B. et al, (2010), Br J Haematol, 148, 80 - 89

• T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).

  Marks DI. et al, (2009), Blood, 114, 5136 - 5145

• Bone Marrow Fibrosis and Diagnosis of Essential Thrombocythemia Reply to J. Thiele et al

  Campbell PJ. et al, (2009), JOURNAL OF CLINICAL ONCOLOGY, 27, E222 - E223

• Classification of Philadelphia Translocation-Negative Myeloproliferative Neoplasms: Its Impact on Data From Clinical Trials Reply

  Campbell PJ. et al, (2009), JOURNAL OF CLINICAL ONCOLOGY, 27, E177 - E178

• Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.

  Mansour MR. et al, (2009), J Clin Oncol, 27, 4352 - 4356

• Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.

  Campbell PJ. et al, (2009), J Clin Oncol, 27, 2991 - 2999

• Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

  Antithrombotic Trialists' (ATT) Collaboration None. et al, (2009), Lancet, 373, 1849 - 1860

• Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.

  Fielding AK. et al, (2009), Blood, 113, 4489 - 4496

• Minimal residual disease is a significant predictor of treatment failure in B lineage adult ALL: final results of the international trial UKALL XII:ECOG 2993

  Patel B. et al, (2009), BRITISH JOURNAL OF HAEMATOLOGY, 145, 44 - 44

• Unlike Paediatric T-ALL, Notch-1 and FBXW7 Mutations Do Not Seem to Predict a Better Outcome in Adult Patients: Data from the UKALLXII/ECOG2993 Protocol.

  Mansour MR. et al, (2008), BLOOD, 112, 885 - 885

• Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

  Rowe JM. et al, (2008), BLOOD, 112, 1138 - 1138

• MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

  Beer PA. et al, (2008), Blood, 112, 141 - 149

• The presence of the factor V Leiden and the prothrombin G20210A polymorphism does not appear to influence the risk of thrombosis in essential thrombocythaernia: results of a nested case control study

  Robinson S. et al, (2008), BRITISH JOURNAL OF HAEMATOLOGY, 141, 75 - 75

• In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

  Goldstone AH. et al, (2008), Blood, 111, 1827 - 1833

• Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.

  Wilkins BS. et al, (2008), Blood, 111, 60 - 70

• Impact of platelet glycoprotein polymorphisms upon clinical events in essential thrombocythaemia patients enrolled in the PT1 trial

  Robinson SE. et al, (2007), BLOOD, 110, 749A - 749A

• Clinical significance of MPL mutations in essential thrombocythemia: Analysis of the PT-1 cohort.

  Beer P. et al, (2007), BLOOD, 110, 208A - 208A

• Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia

  Moorman A. et al, (2007), HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 92, 139 - 139

• Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.

  Moorman AV. et al, (2007), Blood, 109, 3189 - 3197

• Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia

  Moorman AV. et al, (2007), BRITISH JOURNAL OF HAEMATOLOGY, 137, 1 - 1

• Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.

  Fielding AK. et al, (2007), Blood, 109, 944 - 950

• Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.

  Lazarus HM. et al, (2006), Blood, 108, 465 - 472

• Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

  Campbell PJ. et al, (2005), Lancet, 366, 1945 - 1953

• Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

  Rowe JM. et al, (2005), Blood, 106, 3760 - 3767

• JAK2 V617F mutation identifies a biologically distinct subtype of essential thrombocythemia which resembles polycythemia vera.

  Green A. et al, (2005), BLOOD, 106, 77A - 77A

• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  Baigent C. et al, (2005), Lancet, 366, 1267 - 1278

• Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

  Harrison CN. et al, (2005), N Engl J Med, 353, 33 - 45

• Del (9q) AML: clinical and cytological characteristics and prognostic implications.

  Peniket A. et al, (2005), Br J Haematol, 129, 210 - 220

• The outcome of 551 1(st) CR transplants in adult ALL from the UKALL XII/ECOG 2993 study

  Goldstone AH. et al, (2004), BLOOD, 104, 178A - 178A

• The medical research council PT1 trial in essential thrombocythemia.

  Green A. et al, (2004), BLOOD, 104, 5A - 6A

• Sequential quantitative minimal residual disease in BCR-ABL positive acute lymphoblastic leukaemia: Differential observations between major and minor fusion gene rearrangements and variation due to source material

  Gerrard G. et al, (2004), BLOOD, 104, 311A - 311A

• Adult patients with acute lymphoblastic leukemia (ALL) and central nervous system (CNS) leukemia at diagnosis may attain durable complete remissions (CR). Results from the international ALL trial (MRC UKALL-XII/ECOG E2993)

  Lazarus HM. et al, (2004), BLOOD, 104, 204B - 204B

• Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups.

  Kluin-Nelemans HC. et al, (2004), Blood, 103, 4408 - 4415

• Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial.

  Watson M. et al, (2004), Eur J Cancer, 40, 971 - 978

• Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

  Hancock BW. et al, (2004), J Clin Oncol, 22, 53 - 61

• The outcome of 267 Philadelphia positive adults in the international UKALL12/ECOG E 2993 study. Final analysis and the role of allogeneic transplant in those under 50 years.

  Goldstone AH. et al, (2003), BLOOD, 102, 80A - 80A

• Induction therapy for adults with acute lymphoblastic leukemia (ALL): Results of nearly 1,400 patients from the international ALL trial (MRC UKALL XII/ECOG E2993).

  Rowe JM. et al, (2003), BLOOD, 102, 224A - 224A

• Adult patients with acute lymphoblastic leukaemia (ALL) who relapse have a dismal outlook: Results from MRC UKALL XII/ECOG 2993 trial.

  Chopra R. et al, (2003), BLOOD, 102, 880A - 880A

• Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia.

  Clarke R. et al, (2003), J Intern Med, 254, 67 - 75

• CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials.

  Clarke M. et al, (2003), J Clin Oncol, 21, 1798 - 1809

• Intraocular relapse of childhood acute lymphoblastic leukaemia.

  Somervaille TC. et al, (2003), Br J Haematol, 121, 280 - 288

• Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemia.

  Morris EC. et al, (2003), Br J Haematol, 120, 787 - 789

• Treatment of high risk leukaemia - Results of MRC childhood acute lymphoblastic leukaemia study MRC HR-1.

  Kinsey S. et al, (2002), BLOOD, 100, 763A - 763A

• Intraocular relapse of childhood acute lymphoblastic leukemia.

  Somervaille TCP. et al, (2002), BLOOD, 100, 764A - 765A

• The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial.

  Burnett AK. et al, (2002), Br J Haematol, 118, 385 - 400

• Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI.

  Chessells JM. et al, (2002), Br J Haematol, 118, 445 - 455

• Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party.

  Chessells JM. et al, (2002), Leukemia, 16, 776 - 784

• Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99.

  Webb DK. et al, (2002), Br J Haematol, 117, 33 - 39

• Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): Results from the International ALL trial (MRC UKALL XII/ECOG E2993).

  Rowe JM. et al, (2001), BLOOD, 98, 481A - 481A

• Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment.

  Chessells JM. et al, (2001), Arch Dis Child, 85, 321 - 325

• The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

  Kottaridis PD. et al, (2001), Blood, 98, 1752 - 1759

• Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia.

  Webb DK. et al, (2001), Blood, 98, 1714 - 1720

• The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

  Grimwade D. et al, (2001), Blood, 98, 1312 - 1320

• Aim high - Adjuvant interferon in melanoma (high risk): No confirmation yet that low dose interferon is of benefit

  Hancock BW. et al, (2001), BRITISH JOURNAL OF CANCER, 85, 28 - 28

• EVI1 expression in acute myeloid leukaemia.

  Langabeer SE. et al, (2001), Br J Haematol, 112, 208 - 211

• Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993)

  Goldstone AH. et al, (2001), Blood, 98

• Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party.

  Eden OB. et al, (2000), Leukemia, 14, 2307 - 2320

• Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997

  Eden OB. et al, (2000), LEUKEMIA, 14, 2307 - 2320

• The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials.

  Kottaridis PD. et al, (2000), BLOOD, 96, 825A - 825A

• Relationships between age at diagnosis, clinical features and outcome of therapy in children treated in the Medical Research Council trials for acute myeloid leukemia AML 10 and 12.

  Webb DKH. et al, (2000), BLOOD, 96, 318A - 318A

• Prognostic determinants after intensified therapy of childhood lymphoblastic leukemia.

  Vora A. et al, (2000), BLOOD, 96, 466A - 466A

• Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.

  Harrison G. et al, (2000), Ann Oncol, 11, 999 - 1006

• Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial

  Harrison G. et al, (2000), ANNALS OF ONCOLOGY, 11, 999 - 1006

• The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study.

  Lawson SE. et al, (2000), Br J Haematol, 108, 531 - 543

• Philadelphia chromosome plus ve patients with adult acute lymphoblastic leukaemia (ALL), early results from the international ALL trial (MRC UKALL-XII/ECOG E2993).

  Goldstone AH. et al, (1999), BLOOD, 94, 694A - 694A

• Detection of minimal residual disease (MRD) in APL by "real-time" RT-PCR: Analysis of cases entered into the UK MRC ATRA trial.

  Grimwade D. et al, (1999), BLOOD, 94, 625A - 625A

• Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial.

  Watson M. et al, (1999), Cancer, 86, 1231 - 1239

• Improved outcome of acute myeloid leukaemia in Down's syndrome.

  Craze JL. et al, (1999), Arch Dis Child, 81, 32 - 37

• The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial.

  Grimwade D. et al, (1999), BRITISH JOURNAL OF HAEMATOLOGY, 105, 67 - 67

• High bax expression modulates response to treatment and survival in AML.

  Truran LN. et al, (1999), BRITISH JOURNAL OF HAEMATOLOGY, 105, 35 - 35

• Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party.

  Webb DK. et al, (1999), Leukemia, 13, 25 - 31

• The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

  Grimwade D. et al, (1998), Blood, 92, 2322 - 2333

• Leukemic transformation in polycythemia Vera. MPD(UK) Study Group.

  Pearson TC. et al, (1998), Blood, 92, 1837 - 1838

• Association between reproducible flow cytometric methodology for measuring multidrug resistance and remission rates in AML

  Pallis M. et al, (1998), BRITISH JOURNAL OF HAEMATOLOGY, 102, 331 - 331

• The role of molecular diagnosis & residual disease monitoring in APL: Results of the MRC ATRA trial.

  Grimwade D. et al, (1998), BRITISH JOURNAL OF HAEMATOLOGY, 101, 103 - 103

• Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.

  Chessells JM. et al, (1997), Br J Haematol, 98, 945 - 951

• Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party.

  Secker-Walker LM. et al, (1997), Br J Haematol, 96, 601 - 610

Recent Publications

• Prospective evaluation of quality of life in children treated in UKALL 2003 for acute lymphoblastic leukaemia: A cohort study.

  Eiser C. et al, (2017), Pediatr Blood Cancer

• Prospective evaluation of quality of life in children treated in UKALL 2003 for Acute Lymphoblastic Leukaemia (ALL): A cohort study

  Eiser C. et al, (2017), Pediatric Blood and Cancer

• Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.

  Kumar AJ. et al, (2016), Am J Hematol, 91, 1107 - 1112

• in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993

  Ganzel C. et al, (2015), BLOOD, 126

• High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): cytogenetic features, clinical characteristics and outcome.

  Chilton L. et al, (2014), Leukemia, 28, 1511 - 1518